{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:50:01Z","timestamp":1770745801671,"version":"3.49.0"},"reference-count":38,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.3892\/or.2013.2241","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T10:58:11Z","timestamp":1358420291000},"page":"1371-1378","source":"Crossref","is-referenced-by-count":40,"title":["Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation"],"prefix":"10.3892","volume":"29","author":[{"given":"BEI","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XUEYA","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FENGFENG","family":"CAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEIJIE","family":"CHEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ULI","family":"LOESCH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XIAO YAN","family":"ZHONG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,1,17]]},"reference":[{"key":"key20180107214146_b1-or-29-04-1371","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"key20180107214146_b2-or-29-04-1371","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1258\/136218005775544534","article-title":"Advances in the understanding and treatment of ovarian cancer","volume":"11","author":"Morrison","year":"2005","journal-title":"J Br Menopause Soc"},{"key":"key20180107214146_b3-or-29-04-1371","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/GCO.0b013e328011ec99","article-title":"Update on ovarian cancer screening","volume":"19","author":"Munkarah","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"Suppl","key":"key20180107214146_b4-or-29-04-1371","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6601494","article-title":"Primary ovarian cancer chemotherapy: current standards of care","volume":"89","author":"McGuire","year":"2003","journal-title":"Br J Cancer"},{"key":"key20180107214146_b5-or-29-04-1371","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20180107214146_b6-or-29-04-1371","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"key20180107214146_b7-or-29-04-1371","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/14728214.10.2.413","article-title":"Emerging drugs for ovarian cancer","volume":"10","author":"Kelland","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20180107214146_b8-or-29-04-1371","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(02)00847-1","article-title":"Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease","volume":"3","author":"Harries","year":"2002","journal-title":"Lancet Oncol"},{"key":"key20180107214146_b9-or-29-04-1371","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","article-title":"Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis","volume":"3","author":"Harries","year":"2002","journal-title":"Lancet Oncol"},{"key":"key20180107214146_b10-or-29-04-1371","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0162-0134(02)00381-1","article-title":"Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs","volume":"89","author":"Jansen","year":"2002","journal-title":"J Inorg Biochem"},{"key":"key20180107214146_b11-or-29-04-1371","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2004.11.051","article-title":"Activation of PI3K\/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line","volume":"97","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20180107214146_b12-or-29-04-1371","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1477-7827-1-71","article-title":"Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epithelium","volume":"1","author":"Choi","year":"2003","journal-title":"Reprod Biol Endocrinol"},{"key":"key20180107214146_b13-or-29-04-1371","doi-asserted-by":"crossref","first-page":"23477","DOI":"10.1074\/jbc.M313709200","article-title":"Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models","volume":"279","author":"Mabuchi","year":"2004","journal-title":"J Biol Chem"},{"key":"key20180107214146_b14-or-29-04-1371","first-page":"312","article-title":"Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance","volume":"63","author":"Rudin","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107214146_b15-or-29-04-1371","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7164\/antibiotics.27.814","article-title":"Salinomycin, a new polyether antibiotic","volume":"27","author":"Miyazaki","year":"1974","journal-title":"J Antibiot"},{"key":"key20180107214146_b16-or-29-04-1371","first-page":"43","article-title":"Ionophores: their use as ruminant growth promotants and impact on food safety","volume":"4","author":"Callaway","year":"2003","journal-title":"Curr Issues Intest Microbiol"},{"key":"key20180107214146_b17-or-29-04-1371","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"key20180107214146_b18-or-29-04-1371","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbrc.2009.10.042","article-title":"Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells","volume":"390","author":"Fuchs","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107214146_b19-or-29-04-1371","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.bbrc.2010.03.138","article-title":"Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells","volume":"394","author":"Fuchs","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107214146_b20-or-29-04-1371","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2010.03.008","article-title":"The cancer stem cell selective inhibitor salinomycin is a P-glycoprotein inhibitor","volume":"45","author":"Riccioni","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"key20180107214146_b21-or-29-04-1371","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1073\/pnas.1110431108","article-title":"Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells","volume":"108","author":"Lu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107214146_b22-or-29-04-1371","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nature"},{"key":"key20180107214146_b23-or-29-04-1371","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1373\/clinchem.2008.116632","article-title":"Validation of a phosphoprotein array assay for characterization of human tyrosine kinase receptor downstream signaling in breast cancer","volume":"55","author":"Chergui","year":"2009","journal-title":"Clin Chem"},{"key":"key20180107214146_b24-or-29-04-1371","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/1040-8428(94)00124-C","article-title":"Apoptosis and cancer: the failure of controls on cell death and cell survival","volume":"18","author":"Martin","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107214146_b25-or-29-04-1371","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1535-6108(02)00241-6","article-title":"Apoptosis-targeted therapies for cancer","volume":"3","author":"Reed","year":"2003","journal-title":"Cancer Cell"},{"key":"key20180107214146_b26-or-29-04-1371","doi-asserted-by":"crossref","first-page":"9408","DOI":"10.1200\/JCO.2005.01.5594","article-title":"Targeting the cell cycle: a new approach to cancer therapy","volume":"23","author":"Schwartz","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107214146_b27-or-29-04-1371","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif"},{"key":"key20180107214146_b28-or-29-04-1371","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu Rev Cell Dev Biol"},{"key":"key20180107214146_b29-or-29-04-1371","first-page":"7081","article-title":"p53 is a determinant of X-linked inhibitor of apoptosis protein\/Akt-mediated chemoresistance in human ovarian cancer cells","volume":"63","author":"Fraser","year":"2003","journal-title":"Cancer Res"},{"key":"key20180107214146_b30-or-29-04-1371","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4161\/cbt.6.2.3577","article-title":"Curcumin induces G2\/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK","volume":"6","author":"Weir","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"key20180107214146_b31-or-29-04-1371","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/35008115","article-title":"AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1","volume":"404","author":"Medema","year":"2000","journal-title":"Nature"},{"key":"key20180107214146_b32-or-29-04-1371","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","article-title":"Shared principles in NF-kappaB signaling","volume":"132","author":"Hayden","year":"2008","journal-title":"Cell"},{"key":"key20180107214146_b33-or-29-04-1371","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ccr.2004.09.003","article-title":"Nuclear factor-kappaB: the enemy within","volume":"6","author":"Aggarwal","year":"2004","journal-title":"Cancer Cell"},{"key":"key20180107214146_b34-or-29-04-1371","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0898-6568(99)00071-6","article-title":"The p38 signal transduction pathway: activation and function","volume":"12","author":"Ono","year":"2000","journal-title":"Cell Signal"},{"key":"key20180107214146_b35-or-29-04-1371","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/sj.bjp.0706360","article-title":"The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells","volume":"146","author":"Park","year":"2005","journal-title":"Br J Pharmacol"},{"key":"key20180107214146_b36-or-29-04-1371","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key20180107214146_b37-or-29-04-1371","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0065-230X(04)92005-2","article-title":"p38 MAP kinase's emerging role as a tumor suppressor","volume":"92","author":"Bulavin","year":"2004","journal-title":"Adv Cancer Res"},{"key":"key20180107214146_b38-or-29-04-1371","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/ijc.20522","article-title":"Long-term activation of SAPK\/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance","volume":"112","author":"Brozovic","year":"2004","journal-title":"Int J Cancer"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2241\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:42:09Z","timestamp":1515361329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,17]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,1,17]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.3892\/or.2013.2241"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2241","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,17]]}}}